Supplementary Figure S4 from RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy

Ashley V. DiMarco; Mirunalini Ravichandran; Jeff Lau; Anthony Lima; Jennifer A. Lacap; Pablo Saenz-Lopez Larrocha; Eva Lin; Julie Weng; Luca Gerosa; Thomas Hunsaker; Yang Xiao; Monika Miś; Charles Havnar; Wennie Chen; Kai Barck; Klára Tótpál; Oded Foreman; Nicole M. Sodir; Mark Merchant; Danilo Maddalo

doi:10.1158/0008-5472.30029564

Key Points

NCI-H358-RIT1M90I cells were resistant to divarasib but could be resensitized with combination therapy.
In vitro and in vivo experiments demonstrated the efficacy of combining divarasib and migoprotafib.
Resistance to targeted therapy can complicate treatment for lung adenocarcinoma, highlighting the need for innovative combinations.
Understanding the mechanisms of tumorigenesis and therapy resistance is vital for developing better lung cancer treatments.

Implication

Experiments show NCI-H358-RIT1M90I cells resist single-agent divarasib, suggesting combination therapy may improve outcomes.

Abstract

Supplementary Figure S4: (A) NCI-H358-RIT1M90I cells are resistant to divarasib single agent treatment and can be re-sensitized with divarasib and migoprotafib combination both in vitro and in vivo.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

DiMarco et al. (2025) studied this question.

synapsesocial.com/papers/68bb4e016d6d5674bcd02ac8 https://doi.org/10.1158/0008-5472.30029564

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S4 from RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S4 from RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading